EP3169774A4 - Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3 - Google Patents

Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3 Download PDF

Info

Publication number
EP3169774A4
EP3169774A4 EP15822053.3A EP15822053A EP3169774A4 EP 3169774 A4 EP3169774 A4 EP 3169774A4 EP 15822053 A EP15822053 A EP 15822053A EP 3169774 A4 EP3169774 A4 EP 3169774A4
Authority
EP
European Patent Office
Prior art keywords
her3
manufacturing
combination therapy
dendritic cell
cell vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15822053.3A
Other languages
German (de)
English (en)
Other versions
EP3169774A2 (fr
Inventor
Brian J. Czerniecki
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP20172302.0A priority Critical patent/EP3714898A1/fr
Priority claimed from PCT/US2015/041022 external-priority patent/WO2016011422A2/fr
Publication of EP3169774A2 publication Critical patent/EP3169774A2/fr
Publication of EP3169774A4 publication Critical patent/EP3169774A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
EP15822053.3A 2014-07-17 2015-07-17 Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3 Withdrawn EP3169774A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20172302.0A EP3714898A1 (fr) 2014-07-17 2015-07-17 Vaccins cellulaires dendritiques combinée avec thérapie pour bloquer her2 et her3

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462025673P 2014-07-17 2014-07-17
US201462025685P 2014-07-17 2014-07-17
US201462029774P 2014-07-28 2014-07-28
US201562165445P 2015-05-22 2015-05-22
PCT/US2015/041022 WO2016011422A2 (fr) 2014-07-17 2015-07-17 Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20172302.0A Division EP3714898A1 (fr) 2014-07-17 2015-07-17 Vaccins cellulaires dendritiques combinée avec thérapie pour bloquer her2 et her3

Publications (2)

Publication Number Publication Date
EP3169774A2 EP3169774A2 (fr) 2017-05-24
EP3169774A4 true EP3169774A4 (fr) 2018-04-25

Family

ID=55079083

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15822053.3A Withdrawn EP3169774A4 (fr) 2014-07-17 2015-07-17 Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3
EP20172302.0A Withdrawn EP3714898A1 (fr) 2014-07-17 2015-07-17 Vaccins cellulaires dendritiques combinée avec thérapie pour bloquer her2 et her3

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20172302.0A Withdrawn EP3714898A1 (fr) 2014-07-17 2015-07-17 Vaccins cellulaires dendritiques combinée avec thérapie pour bloquer her2 et her3

Country Status (4)

Country Link
EP (2) EP3169774A4 (fr)
JP (2) JP6967963B2 (fr)
CN (1) CN107109365A (fr)
WO (1) WO2016011347A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016190940A1 (fr) * 2015-05-22 2016-12-01 Czerniecki Brian J Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CN100392074C (zh) * 2003-10-15 2008-06-04 上海海欣生物技术有限公司 树突状细胞肿瘤疫苗及其制法和用途
EP2630968A1 (fr) * 2006-06-30 2013-08-28 Baylor Research Institute Cellules dendritiques générées au moyen de GM-CSF et de l'interféron alpha et chargées de cellules cancéreuses inhibées et thermo-traitées
CA2700436C (fr) * 2006-09-28 2017-04-18 John S. Yu Vaccins contre le cancer et methodes de vaccination
WO2010124498A1 (fr) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd Cellule-souche tumorale dont la résistance a été criblée, sa composition antigénique, le chargement de cellules dendritiques antitumorales avec lesdits antigènes, leurs méthodes de préparation, utilisations et kits ainsi qu'un vaccin à base de cellules dendritiques
WO2011029980A1 (fr) * 2009-09-11 2011-03-17 Proyecto De Biomedicina Cima, S.L. Compositions thérapeutiques pour le traitement de maladies provoquées par le pvh
US9862927B2 (en) * 2010-01-22 2018-01-09 Baylor Research Institute Dendritic cell vaccines
EA201290876A1 (ru) * 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
AU2011227447B2 (en) * 2010-03-15 2016-04-14 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
EP2768534A4 (fr) * 2011-10-20 2015-04-01 Neostem Oncology Llc Vaccin anticancéreux présentant un antigène
ES2525205T3 (es) * 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
EP2743344A1 (fr) * 2012-12-11 2014-06-18 DCPrime B.V. Vaccins anticancéreux thérapeutiques dérivés d'une nouvelle lignée de cellules dendritiques
WO2016190940A1 (fr) * 2015-05-22 2016-12-01 Czerniecki Brian J Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELIZABETH FITZPATRICK ET AL: "Cryopreservation of activated DC1 makes large scale dendritic cell vaccines feasible in cancer therapy", CYTOTHERAPY, vol. 17, no. 6, 1 June 2015 (2015-06-01), GB, pages S22 - S23, XP055428214, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2015.03.381 *
TAE HEE HAN ET AL: "Evaluation of 3 Clinical Dendritic Cell Maturation Protocols Containing Lipopolysaccharide and Interferon-[gamma]", JOURNAL OF IMMUNOTHERAPY, vol. 32, no. 4, 1 May 2009 (2009-05-01), pages 399 - 407, XP055156169, ISSN: 1524-9557, DOI: 10.1097/CJI.0b013e31819e1773 *

Also Published As

Publication number Publication date
JP2017522328A (ja) 2017-08-10
JP2020169178A (ja) 2020-10-15
EP3169774A2 (fr) 2017-05-24
CN107109365A (zh) 2017-08-29
EP3714898A1 (fr) 2020-09-30
JP6967963B2 (ja) 2021-11-17
WO2016011347A1 (fr) 2016-01-21

Similar Documents

Publication Publication Date Title
ZA201904717B (en) Therapeutic hpv18 vaccines
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
EP3364949A4 (fr) Vaccins anticancéreux
HK1216991A1 (zh) 癌疫苗及使用其的治療方法
HK1218928A1 (zh) 癌症疫苗及接種方法
EP3193892A4 (fr) Vaccins anticancéreux personnalisés, et procédés correspondants
EP3248640A4 (fr) Collecteur/injecteur de liquide à usage médical
EP3212230A4 (fr) Dosage et administration des anticorps anti-cd40 non fucosylés
IL277780B (en) Retinal ganglion cells and their progenitor cells
EP3180044A4 (fr) Système d'administration thérapeutique implantable et ses procédés
EP3171917A4 (fr) Seringue à partition de doses
EP3020430A4 (fr) Canule pour thérapie d'intégration de catgut
EP3164121A4 (fr) Thérapies par association médicamenteuse contre le cancer et leurs procédés de fabrication et d'utilisation
PT3151831T (pt) Ativação de células cancerígenas com uma dose baixa de naltrexona
EP3091999A4 (fr) Compositions cellulaires améliorées et procédés pour la thérapie du cancer
IL244750A0 (en) Autologous tumor vaccines and methods
EP3107546A4 (fr) Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés
EP3325100A4 (fr) Thérapie combinée utilisant des inhibiteurs de pdk1 et de pi3k
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
PL3124026T3 (pl) Preparat iniekcyjny i sposób jego wytwarzania
HK1223630A1 (zh) 抗- 療法的實施與用量
EP3169774A4 (fr) Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3
EP3184901A4 (fr) Dispositif d'injection de carburant
EP3302539A4 (fr) Fabrication de vaccins multidoses prêts à injecter à base de cellules dendritiques
EP3222289A4 (fr) Vaccin de combinaison adn-peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0784 20100101AFI20171211BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180328

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0784 20100101AFI20180322BHEP

17Q First examination report despatched

Effective date: 20190326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603